Author

O. Sangfelt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Organism:human· 3 Approach:machine learning (classical)· 2 Assay:scRNA-seq· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

A. Malyukova· 2 shared J. Mehtonen· 2 shared M. Heinaniemi· 2 shared M. Lahnalampi· 2 shared O. Lohi· 2 shared S. Teppo· 2 shared A. Azimi· 1 shared A. Hagstrom-Andersson· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Malyukova

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

A. Malyukova, M. Lahnalampi, T. Falques-Costa, P. Polonen, M. Sipola, J. Mehtonen, S. Teppo, J. Viiliainen, O. Lohi, A. Hagstrom-Andersson, M. Heinaniemi, O. Sangfelt

bioRxiv · Mar 27, 2023 · PreprintCancer Biology

Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1 positive pediatric leukemia identifies drug-targetable transcription factor activities

J. Mehtonen, S. Teppo, M. Lahnalampi, A. Kokko, R. Kaukonen, L. Oksa, M. Bouvy-Liivrand, A. Malyukova, S. Laukkanen, P. I. Makinen, S. Rounioja, P. Ruusuvuori, O. Sangfelt, R. Lund, T. Lonnberg, , M. Heinaniemi

This study uses scRNA-seq to analyze B-lymphoid differentiation and leukemic cell states in ETV6-RUNX1-positive pediatric leukemia, identifying drug-targetable transcription factor activities.

bioRxiv · May 27, 2020Cancer Biology

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

L. Vidarsdottir, A. Azimi, I. Sigvaldadottir, A. S. Rahmanto, A. Petri, S. Kauppinen, C. Ingvar, G. Jonsson, H. Olsson, M. Frostvik-Stolt, R. Tuominen, O. Sangfelt, K. Pokrovskaja, J. Hansson, D. Grander, , P. Johnsson

This study shows that PTENP1-AS contributes to BRAF inhibitor resistance and is linked to poor clinical outcomes in stage III melanoma.

bioRxiv · May 3, 2020Cancer Biology